SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-17-005185
Filing Date
2017-05-15
Accepted
2017-05-15 14:02:08
Documents
58
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0317_relmadatherapeutics.htm 10-Q 432430
2 CERTIFICATION f10q0317ex31i_relmadatherap.htm EX-31.1 18917
3 CERTIFICATION f10q0317ex31ii_relmadatherap.htm EX-31.2 18996
4 CERTIFICATION f10q0317ex32i_relmadatherap.htm EX-32.1 7996
5 CERTIFICATION f10q0317ex32ii_relmadatherap.htm EX-32.2 8103
  Complete submission text file 0001213900-17-005185.txt   3201817

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE rlmd-20170331.xml EX-101.INS 570646
7 XBRL SCHEMA FILE rlmd-20170331.xsd EX-101.SCH 32336
8 XBRL CALCULATION FILE rlmd-20170331_cal.xml EX-101.CAL 29712
9 XBRL DEFINITION FILE rlmd-20170331_def.xml EX-101.DEF 151141
10 XBRL LABEL FILE rlmd-20170331_lab.xml EX-101.LAB 338610
11 XBRL PRESENTATION FILE rlmd-20170331_pre.xml EX-101.PRE 235263
Mailing Address 275 MADISON AVENUE, SUITE 702 NEW YORK NY 10016
Business Address 275 MADISON AVENUE, SUITE 702 NEW YORK NY 10016 646-677-3853
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

IRS No.: 455401931 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-55347 | Film No.: 17843168
SIC: 2834 Pharmaceutical Preparations